vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Grove Collaborative Holdings, Inc. (GROV). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $42.4M, roughly 1.1× Grove Collaborative Holdings, Inc.). Grove Collaborative Holdings, Inc. runs the higher net margin — -3.7% vs -23.3%, a 19.5% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -14.3%). Over the past eight quarters, Grove Collaborative Holdings, Inc.'s revenue compounded faster (-11.0% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Grove Collaborative is a benefit corporation headquartered in San Francisco, with an additional office in Portland, Maine. The company makes and sells its own environmentally friendly home and personal care products under its Grove Co. brand, as well as products from other companies.

AMRN vs GROV — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.1× larger
AMRN
$45.1M
$42.4M
GROV
Growing faster (revenue YoY)
AMRN
AMRN
+21.3% gap
AMRN
7.0%
-14.3%
GROV
Higher net margin
GROV
GROV
19.5% more per $
GROV
-3.7%
-23.3%
AMRN
Faster 2-yr revenue CAGR
GROV
GROV
Annualised
GROV
-11.0%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
GROV
GROV
Revenue
$45.1M
$42.4M
Net Profit
$-10.5M
$-1.6M
Gross Margin
53.0%
Operating Margin
35.5%
-3.7%
Net Margin
-23.3%
-3.7%
Revenue YoY
7.0%
-14.3%
Net Profit YoY
33.0%
87.5%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
GROV
GROV
Q1 26
$45.1M
Q4 25
$49.2M
$42.4M
Q3 25
$49.7M
$43.7M
Q2 25
$72.7M
$44.0M
Q1 25
$42.0M
$43.5M
Q4 24
$62.3M
$49.5M
Q3 24
$42.3M
$48.3M
Q2 24
$67.5M
$52.1M
Net Profit
AMRN
AMRN
GROV
GROV
Q1 26
$-10.5M
Q4 25
$-1.2M
$-1.6M
Q3 25
$-7.7M
$-3.0M
Q2 25
$-14.1M
$-3.6M
Q1 25
$-15.7M
$-3.5M
Q4 24
$-48.6M
$-12.6M
Q3 24
$-25.1M
$-1.3M
Q2 24
$1.5M
$-10.1M
Gross Margin
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
47.1%
53.0%
Q3 25
44.7%
53.3%
Q2 25
69.2%
55.4%
Q1 25
59.8%
53.0%
Q4 24
-15.4%
52.4%
Q3 24
38.5%
53.0%
Q2 24
63.4%
53.9%
Operating Margin
AMRN
AMRN
GROV
GROV
Q1 26
35.5%
Q4 25
-12.9%
-3.7%
Q3 25
-22.4%
-6.2%
Q2 25
-22.0%
-7.9%
Q1 25
-39.9%
-8.1%
Q4 24
-84.3%
-16.8%
Q3 24
-59.5%
-14.0%
Q2 24
-0.8%
-13.3%
Net Margin
AMRN
AMRN
GROV
GROV
Q1 26
-23.3%
Q4 25
-2.5%
-3.7%
Q3 25
-15.6%
-6.8%
Q2 25
-19.4%
-8.2%
Q1 25
-37.4%
-8.1%
Q4 24
-78.0%
-25.5%
Q3 24
-59.4%
-2.8%
Q2 24
2.3%
-19.3%
EPS (diluted)
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
$0.00
$-0.06
Q3 25
$-0.02
$-0.08
Q2 25
$-0.03
$-0.10
Q1 25
$-0.04
$-0.10
Q4 24
$-0.12
$-0.34
Q3 24
$-0.06
$-0.04
Q2 24
$0.00
$-0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
GROV
GROV
Cash + ST InvestmentsLiquidity on hand
$307.8M
$8.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$-17.0M
Total Assets
$645.8M
$53.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
GROV
GROV
Q1 26
$307.8M
Q4 25
$302.6M
$8.5M
Q3 25
$286.6M
$8.9M
Q2 25
$298.7M
$10.0M
Q1 25
$281.8M
$9.6M
Q4 24
$294.2M
$19.6M
Q3 24
$305.7M
$50.8M
Q2 24
$306.7M
$78.8M
Total Debt
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$32.2M
Q2 24
Stockholders' Equity
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
$459.3M
$-17.0M
Q3 25
$458.9M
$-16.1M
Q2 25
$464.9M
$-14.0M
Q1 25
$473.7M
$-11.6M
Q4 24
$486.2M
$-8.5M
Q3 24
$531.4M
$1.5M
Q2 24
$551.9M
$686.0K
Total Assets
AMRN
AMRN
GROV
GROV
Q1 26
$645.8M
Q4 25
$670.8M
$53.1M
Q3 25
$659.8M
$54.6M
Q2 25
$670.1M
$57.8M
Q1 25
$655.7M
$59.8M
Q4 24
$685.3M
$65.0M
Q3 24
$750.6M
$105.2M
Q2 24
$799.9M
$131.8M
Debt / Equity
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
21.16×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
GROV
GROV
Operating Cash FlowLast quarter
$-29.0K
Free Cash FlowOCF − Capex
$-62.0K
FCF MarginFCF / Revenue
-0.1%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
$15.3M
$-29.0K
Q3 25
$-12.7M
$-1.0M
Q2 25
$16.6M
$987.0K
Q1 25
$-12.5M
$-6.9M
Q4 24
$-13.3M
$270.0K
Q3 24
$-2.4M
$750.0K
Q2 24
$-2.7M
$1.6M
Free Cash Flow
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
$-62.0K
Q3 25
$-1.2M
Q2 25
$556.0K
Q1 25
$-7.4M
Q4 24
$-95.0K
Q3 24
$264.0K
Q2 24
$1.2M
FCF Margin
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
-0.1%
Q3 25
-2.7%
Q2 25
1.3%
Q1 25
-17.0%
Q4 24
-0.2%
Q3 24
0.5%
Q2 24
2.3%
Capex Intensity
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
1.0%
Q1 25
1.2%
Q4 24
0.7%
Q3 24
1.0%
Q2 24
0.7%
Cash Conversion
AMRN
AMRN
GROV
GROV
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

GROV
GROV

Third Party Products$23.4M55%
Grove Brands$19.0M45%

Related Comparisons